整合骨髓增殖性肿瘤新型治疗策略:推动疾病导向进展
该综述评估了骨髓增殖性肿瘤(MPN)当前治疗手段的多样性增长,指出临床试验终点需转向长期疾病稳定与修饰、分子学缓解、组织形态学改善、并发症减少和生存改善。鉴于疾病异质性和患者内变异,强调优化序贯策略、合理联合方案及以患者特异性轨迹为核心。
要点
- MPN治疗选择显著增多,更多药物获批进入临床。
- 临床试验终点应重视长期疾病稳定、分子学缓解和并发症减少。
- 需优化序贯与联合策略,强调患者特异性轨迹的个体化治疗。
核心结论
- MPN治疗格局复杂演变,需转向以疾病修饰和患者特异性轨迹为核心的个体化策略。
研究设计与样本
- 综述性文章,评估MPN谱系当代治疗手段,未报告系统检索范围或样本量。
主要发现
- 过去十年MPN治疗选择多样性和数量大幅增加,更多药物获批进入临床。
- MPN临床试验终点正转向长期疾病稳定与修饰、分子学缓解、组织形态学改善、并发症减少和生存改善。
- 因疾病异质性和显著患者内变异,需重视优化序贯策略、合理联合方案和患者特异性轨迹。
临床怎么用
- 临床应关注MPN长期疾病稳定与修饰、分子学缓解和并发症减少,而非仅血液学反应和症状脾脏改善。
- 根据患者特异性轨迹优化序贯和联合治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these disorders is required. In parallel, there needs to be a paradigm shift in end-point considerations within MPN clinical trial design, with a growing emphasis on longer term disease stability and modification, molecular responses, histomorphological modification, reductions in complications (e.g. thrombotic complications or disease transformation) and improved survival alongside the conventional goals such as haematological responses and symptom and spleen improvements where relevant. Given the heterogeneity of these disorders, with often marked intrapatient variability, greater consideration must be given to optimised sequencing strategies and rational combination approaches and, importantly, an emphasis on patient-specific trajectories. In this review, we appraise the contemporary therapeutic armamentarium across the MPN spectrum and explore how these advances may best facilitate increasing personalised approaches in an evolving and complex treatment landscape.
引用
- Ngo TQ, Georgiou M, McLornan DP, et al. Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress. Br J Haematol. 2026. PMID: 42422927. doi:10.1111/bjh.70672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。